ClinicalTrials.gg
RecruitingNCT07569432Updated Oct 1, 2026

Investigation of Macrophage Polarization in Peri-implant Health and Peri-implantitis

An observational study in Peri-implantitis, sponsored by Biruni University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Biruni University · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Oct 1, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Peri-Implantitis with a site in Turkey — 16 open to participants now, 19 under way, none of them phase 3. Peri-Implantitis · Turkey.

Planned enrollment
8th of 29
120 · median 87
Started
2025
with 7 others
Observational
29 of 55
6 open now
Primary completion
2027-12
later than 17 of 18 live
Registered
44th of 55
by date
Lead sponsor
2 of 55
Biruni University

Among the 55 studies in Peri-Implantitis with a site in Turkey, this one is the 8th largest by planned enrollment of the 29 observational ones that give a count, is one of 8 that started in 2025, is one of 29 observational ones, reaches primary completion later than 17 of the 18 other live ones, and was the 44th registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

16 of the 55 studies in Peri-Implantitis with a site in Turkey are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Peri-Implantitis with a site in Turkey, or all of them as a file.
02

Study summary

Peri-implantitis is a chronic inflammatory disease characterized by plaque-associated inflammation of the peri-implant mucosa and progressive loss of supporting bone around dental implants, which may ultimately lead to implant failure if left untreated.

It has been demonstrated that cellular and molecular responses of the host immune defense system play a critical role in the pathogenesis of peri-implantitis. Macrophages are key cells in the host immune response and are generally classified into two phenotypes: pro-inflammatory (M1) and anti-inflammatory (M2). While M1 macrophages are actively involved in the early defense response, a shift toward the M2 phenotype is required for the resolution of inflammation and tissue repair.

Smoking has been shown to adversely affect macrophage polarization and function, thereby exacerbating inflammatory responses. Therefore, in the present study, levels of soluable CD163 (sCD163), B cell activating factor (BAFF), tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a proliferation-inducing ligand (APRIL), interferon-gamma (IFN-γ), interleukin-10 (IL-10), interleukin-34 (IL-34), interleukin-35 (IL-35), and arginase activity (ornithine levels) will be evaluated in peri-implant health and peri-implantitis patients with varying disease severity and different smoking statuses. In addition, a comprehensive proteomic analysis will be performed to investigate the relationships among peri-implantitis severity, smoking, and macrophage polarization-related molecules. Baseline periodontal and peri-implant parameters will be recorded for all participants. In the peri-implant health group, tissue samples will be collected during exposure surgery performed for submerged implants, after which participants will be enrolled in supportive peri-implant care. Participants diagnosed with peri-implantitis will receive non-surgical therapy, during which tissue samples will be collected. Periodontal and peri-implant parameters will be reassessed for all participants at baseline, and at 6 and 12 weeks. Healthy peri-implant samples will be collected from submerged implants during exposure surgery. Peri-implantitis samples (probable pocket depth ≥ 6 mm with bleeding on probing) will be obtained during non-surgical therapy using a single stroke along the pocket wall.

03

Conditions studied

  • Peri-implantitis

Keywords

  • peri-implantitis
  • smoking
  • macrophage
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals who applied to Biruni University Faculty of Dentistry for treatment or oral examination will be included in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals who is suitable for the peri-implantitis diagnosis according to the classifications of periodontal and peri-implant diseases and conditions established in 2017.
  • Individuals with at least one bone-level dental implant and scheduled to undergo exposure surgery.

Exclusion criteria

Exclusion Criteria:

  • prior peri-implantitis surgery
  • being diagnosed with disease, genetic disorders, bone metabolism disorders, poorly controlled systemic diseases (such as diabetes or hypertension)
  • pregnancy or lactation
  • having a history of oral , chemotherapy or radiotherapy
  • use of anti-inflammatory drugs within 2 weeks, antibiotics within 3 months,
  • need for prophylactic antibiotics
  • for dental/surgical procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Peri-implant health - smokers

    Individuals with at least one bone-level dental implant, who are current smokers, and are scheduled to undergo exposure surgery.

  • Peri-implant health - non-smokers

    Individuals with at least one bone-level dental implant, who are non-smokers, and are scheduled to undergo exposure surgery.

  • Peri-implantitis - non-smokers

    Individuals with peri-implantitis (non-smokers) were defined as subjects who were non-smokers and presented with bleeding and/or suppuration on gentle probing, an increased probing depth compared to previous examinations, and radiographic evidence of bone loss beyond crestal bone level changes resulting from initial bone remodelling. In cases where previous examination data were not available, peri-implantitis was diagnosed based on the presence of bleeding and/or suppuration on gentle probing, probing depths of ≥6 mm, and radiographic bone levels ≥3 mm apical to the most coronal portion of the intraosseous part of the implant.

  • Peri-implantitis - smokers

    Individuals with peri-implantitis (smokers) were defined as subjects who were current smokers and presented with bleeding and/or suppuration on gentle probing, an increased probing depth compared to previous examinations, and radiographic evidence of bone loss beyond crestal bone level changes resulting from initial bone remodelling. In cases where previous examination data were not available, peri-implantitis was diagnosed based on the presence of bleeding and/or suppuration on gentle probing, probing depths of ≥6 mm, and radiographic bone levels ≥3 mm apical to the most coronal portion of the intraosseous part of the implant.

06

What researchers measure

Primary outcomes

  1. Evaluation of soluable CD163 (sCD163) levels

    sCD163 levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits. The results of the biochemical analyses will be reported as pg/ng.

    Time frame: Baseline

  2. Evaluation of a proliferation-inducing ligand (APRIL) levels

    APRIL levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits. The results of the biochemical analyses will be reported as pg/ng.

    Time frame: Baseline

  3. Evaluation of B-cell activating factor (BAFF) levels

    BAFF levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits. The results of the biochemical analyses will be reported as pg/ng.

    Time frame: Baseline

  4. Evaluation of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) levels

    TWEAK levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits. The results of the biochemical analyses will be reported as pg/ng.

    Time frame: Baseline

  5. Evaluotion of interleukin-10 (IL-10) levels

    IL-10 levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits. The results of the biochemical analyses will be reported as pg/ng.

    Time frame: Baseline

  6. Evaluation of interleukin-34 (IL-34) Levels

    IL-34 levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits. The results of the biochemical analyses will be reported as pg/ng.

    Time frame: Baseline

  7. Evaluation of interleukin-35 (IL-35) levels

    IL-35 levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits. The results of the biochemical analyses will be reported as pg/ng.

    Time frame: Baseline

  8. Evaluation of arginase activity

    Arginase activity in tissue samples collected from the participants will be evaluated using Chinard's method by determined ornithine levels. The results of the biochemical analyses will be reported as pg/ng.

    Time frame: Baseline

Secondary outcomes

  1. Probable pocket depth (PPD)

    Probable pocket depth wiil be measured using a periodontal probe

    Time frame: Baseline and 6th week.

  2. Bleeding on probing (BoP)

    The presence of visible bleeding following periodontal probing will be assessed by visual inspection (+/-). The total bleeding score will be expressed as a percentage.

    Time frame: Baseline and 6th week.

  3. Plaque index

    The presence of visible plaque will be evaluated with a periodontal probe (+/-). The total plaque score will be expressed as a percentage.

    Time frame: Baseline and 6th week.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

Of 33 non-industry observational studies under Peri-Implantitis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 77. This study's planned 24 months is above that.

Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 8 and three quarters within 77.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Dec 2025, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 6, 2026
StartActual
Dec 31, 2025was Apr 2026
Primary completionEst.
Dec 2027
CompletionEst.
Sep 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 2026→Dec 31, 2025 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Start date Apr 2026→Dec 31, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07569432
Lead sponsor
Biruni University
Collaborators
University of Turku, The Scientific and Technological Research Council of Turkey
Responsible party
Burcu KARADUMAN (Prof. Dr., Biruni University) — Principal investigator
First posted
May 6, 2026
Start date
Dec 31, 2025
Primary completion
Dec 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Burcu Karaduman, PhD
study chair · Biruni University
Ulvi K Gursoy, PhD
study chair · University of Turku
Mustafa Yilmaz, PhD
study chair · Istanbul University
Ayse Kaban
principal investigator · Biruni University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion